Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Patients with primary and secondary liver cancer may participate in this study. The purpose
is to perform an analysis of the effects of doxorubicin and its metabolite doxorubicinol on
the body (doxorubicin pharmacokinetics ) after conventional transarterial chemoembolization
(cTACE). cTACE is a procedure in which chemotherapy drugs are injected, followed by an
injection of small beads to block the tumor-feeding arteries. Doxorubicin is a
chemotherapeutic agent used in the cTACE procedure. This study will examine doxorubicin
pharmacokinetics in patients who: 1) receive whole liver cTACE; and 2) receive
super-selective CTACE (i.e., delivered in close proximity to the tumor).